Catalyst Event
Hims & Hers Health Inc (HIMS) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/16/2026, 12:00:00 AM
Stock rose over 13% following news that the FDA will hold an advisory committee meeting in July 2026 to review potentially easing restrictions on certain compounded peptide products.
Korean Translation
미국 FDA가 2026년 7월 자문위원회를 열어 특정 조제 펩타이드 제품에 대한 규제 완화 가능성을 검토할 것이라는 소식에 주가가 13% 이상 상승함.
Related Recent Events
Caris Life Sciences Inc (CAI) · Earnings Release
Next quarterly earnings report scheduled.
6/3/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
5/27/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 earnings release and conference call, for which low impact is estimated as the event has not yet occurred, scheduled.
5/11/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is expected to release its Q1 2026 earnings on May 5, 2026. Analysts forecast an EPS of -$0.21 to -$0.30, with the market pricing in a potential post-earnings stock price move of over 15% scheduled.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Q1 2026 financial results and corporate update scheduled.
5/5/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
Q1 2026 earnings release for May 4, 2026, with analysts forecasting EPS of approximately -$0.27 and revenue of $20.73 million; Medium importance reflects expected volatility, and the event is scheduled.
5/4/2026, 12:00:00 AM